RBC rates Endo at outperform

RBC Capital Markets analyst Ken Trbovich rated Endo Pharmaceuticals Holdings, Inc. at outperform, above average risk on news that the Food and Drug Administration's bioequivalence recommendations for generic Lidoderm are less stringent than expected. With Endo's stock down 12% in post-market trading Tuesday night, the analyst believes he stock is oversold - an attractive entry-point for investors with a longer-term investment horizon. Generic Lidoderm is at least 2.5 years away. Shares of the Chadds Ford, Pa.-based pharmaceutical company were down $4.50, or 13.27%, at $29.41. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.